文献速递其他结缔组织病

系统性硬化症相关间质性肺病短期进展预测长期生存:两项独立临床试验队列

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
PubMed 文献 · Ann Rheum Dis · 2018-11-08

研究基于SLS I和II两项随机对照试验,评估系统性硬化症相关间质性肺病患者的生存及预测因素。中位随访8年后,SLS I中42%患者死亡,死因多归因于SSc。基线皮肤评分高、年龄大以及2年内FVC和DLCO下降与死亡风险增加独立相关;Cox模型在SLS II中识别出相同的死亡预测变量。

要点

  • 2年内FVC和DLCO下降比基线FVC和DLCO更能预测死亡。
  • 基线皮肤评分高和年龄大是独立的死亡风险因素。
  • SLS I和II中治疗组间至死亡时间无显著差异。

核心结论

  • 在SSc-ILD患者中,2年内FVC和DLCO下降是比基线FVC和DLCO更好的死亡预测因素。

研究设计与样本

  • SLS I随机分配158例SSc-ILD患者接受1年口服环磷酰胺(CYC)或安慰剂。
  • SLS II随机分配142例患者接受1年口服CYC后1年安慰剂或2年霉酚酸酯。
  • 采用计数过程Cox比例风险模型识别长期死亡相关变量,并用联合模型进行内部验证。

主要发现

  • SLS I中位随访8年后,42%患者死亡,已知死因多归因于SSc。
  • SLS I和II中治疗组间至死亡时间无显著差异。
  • SLS I中基线皮肤评分高、年龄大以及2年内FVC和DLCO下降与死亡风险增加独立相关。
  • Cox模型在SLS II数据中识别出相同的死亡预测变量。

临床怎么用

  • 临床中应关注SSc-ILD患者2年内FVC和DLCO的短期变化,其比基线值更能提示长期死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess survival and identify predictors of survival in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung Studies (SLS) I and II. METHODS: SLS I randomised 158 patients with SSc-ILD to 1 year of oral cyclophosphamide (CYC) vs placebo. SLS II randomised 142 patients to 1 year of oral CYC followed by 1 year of placebo vs 2 years of mycophenolate mofetil. Counting process Cox proportional hazard modelling identified variables associated with long-term mortality in SLS I and II. Internal validation was performed using joint modelling. RESULTS: After a median follow-up of 8 years, 42% of SLS I patients died, and when known the cause of death was most often attributable to SSc. There was no significant difference in the time to death between treatment arms in SLS I or II. Higher baseline skin score, older age, and a decline in the forced vital capacity (FVC) and the diffusing capacity for carbon monoxide (DLCO) over 2 years were independently associated with an increased risk of mortality in SLS I. The Cox model identified the same mortality predictor variables using the SLS II data. CONCLUSION: In addition to identifying traditional mortality risk factors in SSc (skin score, age), this study demonstrated that a decline in FVC and DLCO over 2 years was a better predictor of mortality than baseline FVC and DLCO. These findings suggest that short-term changes in surrogate measures of SSc-ILD progression may have important effects on long-term outcomes.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Volkmann ER, Tashkin DP, Sim M, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2018. PMID: 30409830. doi:10.1136/annrheumdis-2018-213708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。